1-2 of 2
Laksmi Wilson
Close
Sort by
Journal Articles

A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma

Jake Shortt, Brian Poligone, Vincent Ribrag, Pier Luigi Zinzani, Dima El-Sharkawi, Jan Walewski, Anca Prica, Laksmi Wilson, Sonia Souza, Harold N. Keer, Jason A. Taylor, Enrica Marchi
Journal: Blood
Blood (2022) 140 (Supplement 1): 12033–12034.
https://doi.org/10.1182/blood-2022-158650
Published: 2022
Journal Articles

Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA)

Hagop M. Kantarjian, MD, Gail J. Roboz, MD, Patricia L. Kropf, MD, Karen W.L. Yee, MD, Casey L. O'Connell, MD, Raoul Tibes, MD PhD, Katherine J. Walsh, MD, Nikolai A. Podeltsev, MD, Elizabeth A. Griffiths, MD, Elias Jabbour, Guillermo Garcia-Manero, MD, David A. Rizzieri, MD, Wendy Stock, MD, Michael R. Savona, MD, Todd L. Rosenblat, MD MS, Jesus G. Berdeja, MD, Laksmi Wilson, James N. Lowder, MD, Pietro Taverna, PhD, Yong Hao, PhD, Mohammad Azab, MD, Jean-Pierre Issa, MD
Journal: Blood
Blood (2015) 126 (23): 458.
https://doi.org/10.1182/blood.V126.23.458.458
Published: 2015